Bio-Gene Technology (ASX: BGT) has released new data confirming that its lead compound Flavocide delivers strong activity against ticks responsible for spreading Lyme disease in the United States. Importantly, the prototype formulation also displayed residual protection lasting up to four weeks, pointing to a durable solution that could support both public health programs and animal health markets. Bio-Gene believes this combination of efficacy and safety positions Flavocide as a potential tool for integrated tick management strategies, with broad appeal to public health agencies and veterinary markets. Responding to an Urgent Health ChallengeTick-borne diseases continue to rise across North America, with Lyme disease at the forefront of concern. Bio-Gene sees the opportunity extending beyond public health into companion animals and livestock, markets that also face rising pressure from parasites and a shortage of safe, long-lasting products.